VIR News and Press, Vir Biotechnology Inc. From 12/20/21

Can-Fite BioPharma (NYSE:CANF) +71% liver cancer patient treated with can-Fite’s Namodenoson clears all cancer lesions under open label extension of phase II study. Society Pass Incorporated (NASDAQ:SOPA) +35% on being added to the Russell 2000 Index. Verso (NYSE:VRS) +3...

The healthcare stocks in the S&P 500 with a ~2.5% gain outperformed all other sectors in the broader index thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%. Am...

LONDON and SAN FRANCISCO, Dec. 17, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Commission (EC) has granted marketing authorization to Xevudy (sotrovimab) for the early treatment of COVID-19. Sot...

Shares of Adagio Therapeutics (ADGI +63.8%) are surging in morning trading after a Jefferies analyst said that pre-print data suggests that its COVID-19 antibody ADG20 retains neutralization activity against the Omicron variant. Michael Yee cited independent labs -- one at Columbia University...

Calliditas Therapeutics (NASDAQ:CALT) +38% on FDA approval for kidney disease therapy. Kaixin Auto (NASDAQ:KXIN) +27% on a partnership agreement with Bujia for 10k new energy trucks. Biomerica (NASDAQ:BMRA) +18% preliminary second quarter revenue increase of approxima...

Shares of Vir Biotechnology (NASDAQ: VIR) jumped 12% on Wednesday after the company shared promising data for its COVID-19 antibody treatment. Vir said that sotrovimab, the investigational monoclonal antibody treatment it developed with healthcare giant GlaxoSmithKline ...

Gainers: Biofrontera (NASDAQ:BFRI) +26%, Gemini Therapeutics (NASDAQ:GMTX) +19%, Vir Biotechnology (NASDAQ:VIR) +14%, Mesoblast (NASDAQ:MESO) +14%, Tandem Diabetes Care (NASDAQ:TNDM) +10% Losers: Atai Life Sciences (NASDAQ:ATAI) -24%, Alzamend...

Preclinical data from Vir Biotechnology (NASDAQ:VIR) on sotrovimab found that its has neutralizing activity against the Omicron variant of COVID-19 in an in vitro model. The data, published in BioRxiv, also found that sotrovimab, which is being developed with GlaxoSmithKline (NYSE:GSK) was ef...

– Data demonstrate sotrovimab, developed by Vir in conjunction with GlaxoSmithKline, continues to retain in vitro neutralizing activity against all tested variants of concern, including Omicron – SAN FRANCISCO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. ...

COVID-19 antibody therapies developed by Eli Lilly (NYSE:LLY) and Regeneron (NASDAQ:REGN) lose most of their activity when exposed to the newly detected Omicron variant of coronavirus, a lab-based study conducted by a group of German researchers has found. The antibody therapies in question, ...